Vita Life Sciences Limited provided earnings guidance for the first half of 2020. For the period, the company expects sales of around $21.5 million to $22.0 million, which is higher than PCP. Higher sales contribution from core markets, including export channel underpins this result. EBIT of around $3.7 million to $4.1 million, which is higher the PCP. Higher sales combined with lower marketing and operational expenses against PCP underpins this result.